GlaxoSmithKline, the pharmaceutical group, has agreed to pay up to $3.6bn (£2.5bn) for Stiefel Laboratories of the US, significantly boosting its presence in dermatology as part of a growing portfolio of consumer healthcare businesses.

The deal represents the largest acquisition so far undertaken by GSK under Andrew Witty, the chief executive appointed last June.